Replies to post #355531 on Amarin Corp Plc (AMRN)

[dukesking]

NS, Thanks for the follow up and the great explanation.

[Meowza]

Thanks for the post, I enjoyed reading it.

If H falls on their face attempting to invalidate, what are the repercussions regarding R-It regulatory rexclusivity?

(after the fourth R i decided to lean into it)

[north40000]

The present civil action filed by Amarin in Delaware is a standard patent infringement suit without H-W overtones. You correctly observe that H et al have the opportunity to plead non infringement as well as patent(s) invalidity. You may want to rethink the idea of a 2nd H-W suit being filed before R-I patents with CVD indication coverage expire in the 2030s.

Perhaps I do not understand your position as you present it.

[sts66]

Hikma cannot challenge R-IT patents before ANDA exclusivity ends this Dec, then there's a 30 month stay before FDA will accept an ANDA challenging R-IT patents. All Hikma can argue is whether they are infringing R-IT patents or not, cannot argue the patents are invalid - to do otherwise would allow them to bypass that 30 month hurdle.